Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease-Reference-Cited by-同舟云学术

Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease

Published:2016 Issue:7 Volume:23 Page:848-856
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Nozue Tsuyoshi¹,Hattori Hiroaki²,Ogawa Kazuyuki²,Kujiraoka Takeshi²,Iwasaki Tadao²,Michishita Ichiro¹

Affiliation:

1. Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital

2. Department of Advanced Medical Technology and Development, BML, Inc.

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/23/7/23_33407/_pdf

Reference39 articles.

1. 1) Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci, 2007; 32: 71-77

2. 2) Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem, 2006; 387: 871-877

3. 3) Lambert G, Krempf M, Costet P. PCSK9: a promising therapeutic target for dyslipidemias? Trends Endocrinol Metab, 2006; 17: 79-81

4. 4) Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res, 2007; 48: 763-767

5. 5) Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest, 2006; 116: 2995-3005

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelial dysfunction: molecular mechanisms and clinical implications;MedComm;2024-07-22

2. Is Sortilin an Indicator of Subclinical Atherosclerosis in Patients with Psoriasis?;Journal of Clinical Practice and Research;2024

3. Targeting PCSK9 to tackle cardiovascular disease;Pharmacology & Therapeutics;2023-09

4. The association of plasma sortilin with essential hypertension and subclinical carotid atherosclerosis: A cross-sectional study;Frontiers in Cardiovascular Medicine;2022-10-12

5. Deciphering Mechanisms of Action of Sortilin/Neurotensin Receptor-3 in the Proliferation Regulation of Colorectal and Other Cancers;International Journal of Molecular Sciences;2022-10-06